It is now nine years since the isolation of the dystrophin gene, which is mutated in Duchenne and Becker forms of muscular dystrophy [1] . In that time, enormous progress has been made in understanding the normal behaviour of the inconveniently large dystrophin gene -it is currently estimated at 2.5 million bases, has at least 6 promoters and nearly 80 exons (Fig. la) . In addition, numerous studies have revealed that the non-mutant dystrophin is part of a complex of proteins at the muscle cell membrane [2, 3] . Progress towards genuine new insights into the function of dystrophin in normal muscle, and more particularly into how to translate such understanding as there is into therapies and prognostic tools, has proved harder to achieve but now seems to be in sight.
These unresolved issues were one focus of the group f cell biologists, geneticists and medical researchers at a recent meeting*. But although progress towards improved therapies remains a central goal of research, study of the dystrophin protein itself is beginning to shed light on unexpected areas of cell and developmental biology, and it is these that will form the focus of this article. It is now apparent, for example, that the dystrophin-associated complex of proteins and glycoproteins that was first found in muscle is in fact present in many cell types, and presumably may be adapted for a variety of functions. The complex was first identified through its association with dystrophin and the defects that occur in dystrophic muscle, but this may not adequately reflect its importance throughout the body.
Before considering the non-muscle functions of the complex, let us first look at its structure and function in muscle cells. The associations between the members of the dystrophin-associated complex -who holds hands with whom -are becoming increasingly clear. Results have come from traditional biochemical techniques, such as affinity chromatography and immunoprecipitation, along with the less traditional analysis of how purified proteins interact with each other when the complex is electrophoresed on a gel and then overlaid with a particular purified protein (Kevin Campbell, University of Iowa, Iowa City, USA; Eijiro Ozawa, National Institute of Neurosciences, Tokyo, Japan; see [2, 3] and references therein).
In addition, the genes encoding members of the complex are now being cloned and the proteins given names.
As shown in Figure 2a , the ot and P3 dystroglycans, which are the processed products of a single dystroglycan gene, are central to the dystrophin-associated complex; dystroglycan is a transmembrane glycoprotein that interacts with both dystrophin on the inside of the cell and c dystroglycan on the outside [2] . As dystrophin binds to filamentous actin and a dystroglycan binds to the extracellular matrix protein merosin (a form of laminin), these three components of the complex provide a bridge that links the actin cytoskeleton, the cell membrane and the extracellular matrix. It is tempting to think that the question of how mutations in the dystrophin gene cause muscular dystrophy is therefore solved: muscle cells lose the anchorage between their membranes and both the cytoskeleton and the extracellular matrix if dystrophin is mutated -and perhaps, once the details are understood, this hypothesis will prove to explain many of the clinical aspects of Becker and Duchenne muscular dystrophies. But, as Louise Anderson (Muscular Dystrophy Research Laboratories, Newcastle-upon-Tyne, UK) pointed out, trying to relate the particular mutations found in people with muscular dystrophy to the expected effect of each mutation on the function of dystrophin has not yet yielded any unbreakable rules for the clinician to follow. Furthermore, a long-observed puzzling phenomenonthat there are elevated serum levels of a muscle cytosolic enzyme, creatine kinase, in people who will develop muscular dystrophy but who do not yet have any clinical manifestation of the disease -suggests that the alterations in dystrophic muscle may be more complicated than simply a catastrophic loss of anchorage.
Some of the subtleties of function may be provided by other members of the complex, of which there may be as many as ten (and counting). It is not entirely surprising to learn that the gene encoding a second member of the complex (called adhalin, from the Arabic for muscle) has recently been identified as mutated in an autosomal recessive muscular dystrophy (severe childhood autosomal recessive muscular dystrophy, SCARMD) [4] . It is now apparent that people with adhalin-deficient dystrophies may have defects in either the adhalin gene itself (Steve Roberds and Campbell, University of Iowa; Jean-Claude Kaplan, Institut Cochin de Genetique Mol6culaire, Paris) or, presumably, in some other gene whose product affects the distribution or level of adhalin. A third congenital form of muscular dystrophy (congenital Fig. 1 . Structures of the dystrophin gene and protein (a), and the family of dystrophin-related proteins (b). In (a), the various promoters are indicated above the gene and the approximate number of exons within each portion of its length are shown below; the letter beside each promoter indicates the tissue in which transcripts from that promoter were originally described (C, cortex; M, muscle; P, Purkinje cells; R, retina; B/K, brain/kidney; S, Schwann cells; G, general or glial cells). See [11] for details of the 'R' promoter and [13, 14] for designation of the functional domains of dystrophin; the 'B/K' promoter is mentioned in the text. Adapted from [15] ; see [3] for more recent details. muscular dystrophy, CMD) is associated with decreased levels of merosin, the muscle form of laminin, around muscle cells and in intramuscular nerves [5] . But although CMD has been linked to the region of chromosome 6 that harbours the merosin gene in some merosindeficient families, no mutations have yet been found in the merosin gene itself (Michel Fardeau, INSERM U 153, Paris). All of these observations are consistent with a model in which the integrity of the dystrophin-associated complex is important in the normal functioning of muscle cells, and loss of one or more members of the complex is sufficient to cause dystrophic disease.
Although much of our understanding of the dystrophinassociated complex has come from studies aimed directly at understanding its dysfunction in dystrophic muscle, other researchers have stumbled across the complex from other directions. In particular, researchers who have been trying for a long time to understand the mechanism underlying synaptogenesis, as exemplified by the vertebrate neuromuscular junction, have now found that the proteins they have been studying form part of the dystrophin-associated complex. Thus, syntrophin (now known as a syntrophin) was first identified as a consequence of its prevalence in synaptic membranes, and it was subsequently purified from the specialized synapserich electric organ of the electric ray, Torpedo. The genes encoding a syntrophin and two 13 isoforms have recently been cloned (Louis Kunkel, The Children's Hospital, Boston, USA; Stanley Froehner, University of North Carolina, Chapel Hill, USA; Campbell; Ozawa). The three syntrophins have distinct tissue distributions and associate differentially with different forms of the dystrophin-associated complex: ot syntrophin seems to be the prevalent form in skeletal muscle, whereas the 3s are also found in most other tissues; 32 syntrophin is localized to the neuromuscular synapses within muscle cells.
Studies using the Torpedo electric organ to analyse how acetylcholine receptors come to be clustered in the postsynaptic membrane of the neuromuscular junction have also led researchers to the dystrophin-associated complex. Clustering of the receptors is an essential element of synapse formation, as a very high concentration of receptors is required to produce sufficient depolarization of the muscle cell membrane for an action potential to be elicited. Last year, a number of workers studying agrin, an extracellular glycoprotein involved in the signalling between nerve and muscle that leads to clustering of acetylcholine receptors, discovered that agrin binds specifically to ao dystroglycan in the postsynaptic membrane (see [6] and references therein). Although there was initial caution about the idea that ot dystroglycan might be the functional receptor that receives the agrin signal, as it seemed to lack the necessary specificity of binding and the means by which to transduce signals [6] , it now in relaying agrin's signal is not entirely fanciful. Perhaps association with agrin rather than merosin affects binding of the dystroglycans to other members of the complex in addition to dystrophin/utrophin. Both aficionados of the neuromuscular junction and others at the meeting suggested that the complex might have a signalling role rather than simply a structural one; perhaps the complex signals agrin's arrival by associating with a more traditional signal-transducing receptor. This would be consistent with the phosphorylation of synaptic proteins, including the acetylcholine receptor itself, that is associated with agrin-induced receptor clustering. Fig. 2 . Interactions between members of the dystrophin-associated complex in (a) most of the skeletal muscle cell membrane, and (b) the neuromuscular junction (note that the 43K protein illustrated here is not the same as the 43 kD Torpedo protein discussed in the text). The indication that utrophin associates with complexes that attach to agrin outside the cell, whereas dystrophin links exclusively with merosin-linked complexes, is purely speculative.
seems that a dystroglycan does bind to agrin with an affinity similar to that of agrin's binding to postsynaptic membranes Justin Fallon, Worcester Foundation, Shrewsbury, USA). There remains a problem of specificity, in that (x dystroglycan binds equally well in vitro to clusterinducing and non-inducing splice variants of agrin, but this may reflect limitations in the assay rather than in the hypothesis that o dystroglycan is an important agrin receptor (Fallon; James Campanelli, Stanford University, Stanford, USA).
How could ao dystroglycan or the dystrophin-associated complex be involved in signalling the arrival of agrin across the cell membrane? One popular hypothesis is that the binding of agrin (rather than merosin) outside the cell drives association of the cytoplasmic portion of the complex with the ubiquitously distributed utrophin (Fig. 2b) , rather than the muscle-specific dystrophin. Although dystrophin and utrophin are broadly similar in structure (and both are similar to the cytoskeletal proteins oa actinin and at and 3 spectrin; Fig. lb) , and both are known to associate with members of the complex and with the actin-based cytoskeleton (Kay Davies, Oxford University, Oxford, UK), the differences between the two might lead to profound -although as yet unknown -effects on the function of the complex and the proteins to which it connects. Utrophin is indeed found concentrated in neuromuscular junctions and it localizes to the domains richest in acetylcholine receptors both in the adult and during embryonic development (Clark Slater, Newcastle University, Newcastleupon-Tyne, UK). As agrin induces a clustered localization of utrophin as well as of acetylcholine receptors, other members of the dystrophin-associated complex and proteins of the cytoskeleton and extracellular matrix (Fallon, Campanelli), the idea of a role for the complex One slightly mysterious player whose precise role remains to be determined is a 43 kD protein that associates with acetylcholine receptors and can drive their clustering, although it does not seem to be directly associated with the dystrophin/utrophin-associated complex Jonathan Cohen, Harvard Medical School, Boston, USA; Froehner). Transfection of cells with cDNAs encoding the 43 kD protein induces clustering of both acetylcholine receptors and components of the dystrophin/utrophin-associated complex, so it seems to have some role in drawing the complex into an association with receptor clusters at the neuromuscular junction (Cohen). In the Torpedo electric organ, at least, there is also an 87 kD protein ('87K') that associates with tx syntrophin and dystrophin and co-localizes with acetylcholine receptors in clusters; 87K is homologous to the carboxy-terminal portion of dystrophin ( Fig. 1) and it may correspond to a similar-sized protein found in the dystrophin-associated complex isolated from mammalian muscle cells (Cohen; Ozawa). Even once the roles of these two players are clarified, the problem of how to build a synapse would still be far from solved -not least because stoichiometry calculations suggest that there may be only one ax dystroglycan molecule per 50 acetylcholine receptors and 43 kD protein molecules to be clustered (Fallon) -but the data available at present are consistent with a 'corral' model, in which a mesh of utrophin/dystrophin-associated complexes forcibly clusters the 43 kD molecules and acetylcholine receptors, along with some other key synaptic molecules, into patches in the postsynaptic membrane (Campanelli; Fallon; Slater).
Have agrin and utrophin simply usurped the dystrophinassociated complex that is present throughout most of the muscle cell membrane and specialized it for the development of the postsynaptic membrane sites responsible for receiving acetylcholine signals? Some tantalizing preliminary experiments done by Fallon's colleague, Mary Nastuk, suggest that the role of the complex in synaptogenesis may go beyond the neuromuscular junction and into the nervous system. In cultured hippocampal pyramidal cells, agrin binds to both cell-bodies and dendrites, and agrin-binding sites co-localize with some synapses, as identified by synaptic vesicle protein localization. So perhaps agrin -and, by implication, the c dystroglycan to which it binds -will prove to function in synaptogenesis in the central nervous system as well as in the neuromuscular junction.
In addition to the possible role of the dystrophin-associated complex in synaptogenesis, there is increasing evidence that some of the many splice variants of dystrophin are expressed specifically in the brain. These observations may have relevance to the neurological problems that can be associated with various muscular dystrophies. David Yaffe and colleagues (Weizmann Institute of Science, Rehovot, Israel) found that the transcript encoding Dp71, the truncated dystrophin variant transcribed from the 'G' promoter ( Fig. 1) , is found in many tissues, including brain, but not skeletal muscle. Dp71 production is unaffected by most dystrophin mutations that cause Becker or Duchenne muscular dystrophies, but in the few cases in which it is affected, neurological complications seem always to have been found. Although expression of Dp71 in dystrophic muscle restores the assembly of much of the complex, it cannot substitute functionally for full-length dystrophin -the muscle remains dystrophic [7, 8] . Nevertheless, Dp71 could have a distinct function in nerve cells. Kunkel described a new dystrophin truncation variant, Dpl40, which is produced by a transcript from a newly identified promoter (B/K, pink in Fig. 1 ) and expressed at high levels, particularly in parts of the brain as well as in the kidneys [9] . Although there is a considerable history of publications attempting to link particular deletions of the dystrophin gene to mental impairment in patients (and to behavioural defects in mouse models of muscular dystrophy), from which no clear consensus has emerged, both Kunkel and Yaffe suggested that the nervous-system-specific truncation variants of dystrophin might (like dystrophin itself) be important for mental function; an examination of dystrophin variants in patients with particular dystrophin mutations and disease characteristics might lead to new diagnostic and prognostic indicators, if not directly to any new therapy.
A third link between the nervous system and the dystrophin-associated complex was presented by Kiichiro Matsumura (Teikyo University School of Medicine, Tokyo, Japan), who has used confocal immunocytochemistry as well as gel overlays to study dystroglycan in the peripheral nervous system. The a dystroglycan purified from peripheral nerves can bind to merosin in gel overlays, and ao dystroglycan is present in the outer membrane of Schwann cell myelin sheaths [10] . Although both the Dpl 16 dystrophin variant (transcribed from the 'S' dystrophin promoter; Fig. la) and full-length utrophin can be isolated from these cells, in this case they do not seem to be physically associated with ao dystroglycan. The precise function of the dystrophin/utrophin-associated complex in the peripheral nervous system remains to be resolved, but it is intriguing to note that both dy/dy dystrophic mice and some people with CMD have both a deficiency of merosin and defects in peripheral nerve myelination (Francesco Muntoni and Caroline Sewry, Hammersmith Hospital, London, UK; personal communication). Finally, the newly identified Dp260 dystrophin variant (transcribed from the 'R' promoter; Fig la) is normally expressed in the outer plexiform layer of the mouse retina and seems to be essential for retinal function [11] . Thus, mdxCv 3 mutant mice, which are predicted to lack Dp260, have abnormal retinal electrophysiology, whereas mdx mice, which should have Dp260 but not full-length dystrophin in their retinas, have normal electroretinograms. The mice reflect the spectrum of human disease, as some people with Becker or Duchenne dystrophies also have abnormalities of retinal electrophysiology, perhaps depending on whether or not their dystrophin mutation affects the Dp260 isoform.
Components of the dystrophin-associated complex are expressed at significant levels in numerous tissues. For example, the dystroglycans are found at high levels in tissues as diverse as placenta and kidney, as well as in the nervous system and in muscle [12] . In addition, the carbohydrate moieties of the dystroglycans may vary in a tissue-specific way, which would be expected to have profound effects on their interactions with the extracellular matrix. The precise purposes for which the complex may have been adapted in all these tissues await further analysis, but evidence that the dystrophin-associated complex is present (and presumably functional) in tissues other than muscle, and in association with proteins other than full-length dystrophin, is piling up.
